FAGEST 250 

FAGEST 250 is a long-acting progesterone formulation developed to provide sustained hormonal support in obstetric care. Each 1 ml injection contains Hydroxyprogesterone Caproate 250 mg, a well-established progestin used to help maintain pregnancy in women requiring progesterone supplementation. It is particularly valuable in patients with a history of preterm birth or those identified as high-risk, where maintaining uterine stability is critical. The depot nature of the formulation ensures gradual release of the drug, allowing consistent plasma levels over an extended period and improving treatment compliance.

Mechanism of Action

Hydroxyprogesterone Caproate exerts its effect by replicating the physiological actions of natural progesterone. It plays a key role in maintaining uterine quiescence by reducing the sensitivity of the myometrium to stimulatory signals. This helps in minimizing uterine contractions that can trigger premature labor. In addition, it supports the integrity of the endometrial lining and modulates inflammatory responses associated with cervical ripening. Together, these actions contribute to prolonging pregnancy and reducing the likelihood of early delivery in susceptible patients.

Indications

FAGEST 250 is indicated in the following situations:

• Prevention of preterm birth in women with a prior history of spontaneous preterm delivery
• Progesterone supplementation in cases of documented deficiency
• Supportive management in recurrent pregnancy loss, where progesterone support is considered beneficial
• Other gynecological and obstetric conditions as directed by the treating physician

Key Benefits

FAGEST 250 offers a combination of clinical reliability and patient convenience:

• Long-acting depot formulation ensures sustained therapeutic levels
• Helps reduce the incidence of preterm labor in high-risk pregnancies
• Provides consistent hormonal support critical for pregnancy maintenance
• Enables once-weekly dosing, improving adherence
• Well-recognized and widely used in obstetric practice

Dosage and Administration

FAGEST 250 is administered via deep intramuscular injection and should be given under the supervision of a qualified healthcare professional. The commonly recommended regimen involves once-weekly administration; however, the exact dosage, timing, and duration of therapy should be individualized based on patient condition and physician discretion. Proper adherence to the prescribed schedule is essential for optimal therapeutic benefit.

Why Choose FAGEST 250?

FAGEST 250 is formulated to meet the practical needs of clinicians managing high-risk pregnancies. Its stable, long-acting profile ensures dependable performance, while its established clinical utility makes it a trusted option in progesterone therapy. The product is developed in line with stringent pharmaceutical quality standards, offering assurance in terms of safety, efficacy, and consistency. For clinicians seeking a reliable progesterone solution with convenient dosing and proven support in pregnancy care, FAGEST 250 presents a dependable choice.